Skip to main content

Freedom of information requests

FOI 2840 2022/23

The incidence and treatment of fungal infections in the UK

Published 21 September 2023

The incidence and treatment of fungal infections in the UK

Questions

Q1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs?

Amphotericin B (Ambisome)
Caspofungin (Cancidas)
Isavuconazole (Cresemba)
Posaconazole (Noxafil)
Voriconazole (VFEND)

Q2a. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillosis (ICD10 code: B44)?

Q2b. Of the above patients diagnosed with Aspergillosis in the last 12 months, how many patients were treated with the following drugs:

Amphotericin B (Ambisome)
Caspofungin (Cancidas)
Isavuconazole (Cresemba)
Posaconazole (Noxafil)
Voriconazole (VFEND)

Q3a. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?

Q3b. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs:

Amphotericin B (Ambisome)
Isavuconazole (Cresemba)
Posaconazole (Noxafil)

Response

Q1.

Drug

Number_of_patients

 Isavuconazole (Cresemba)

19

 Posaconazole (Noxafil)

138

 Voriconazole (VFEND)

159

Amphotericin B (Ambisome)

205

Caspofungin (Cancidas)

34

 

Q2a.

114

 

Q2b.

Drug

Number_of_patients

 Isavuconazole (Cresemba)

0

 Posaconazole (Noxafil)

7

 Voriconazole (VFEND)

21

Amphotericin B (Ambisome)

4

Caspofungin (Cancidas)

3

 

Q3a.

3

 

Q3b.

Drug

Number_of_patients

 Isavuconazole (Cresemba)

1

 Posaconazole (Noxafil)

1

Amphotericin B (Ambisome)

1